10 powodów, dla których warto stosować ramipril Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
wrz 30, 2017
Słowa kluczowe:
ramipril, inhibitory konwertazy angiotensyny, ryzyko sercowo-naczyniowe
##plugins.themes.bootstrap3.article.main##
Abstrakt
Inhibitory konwertazy angiotensyny to jedna z podstawowych grup leków w kardiologii. Blokowanie układu renina–angiotensyna–aldosteron jest także kluczowym aspektem leczenia pacjentów z przewlekłą chorobą nerek. Obecnie odchodzi się od pojęcia efektu klasy, wybór konkretnego inhibitora konwertazy angiotensyny może być więc trudny. W artykule opisano szczegółowo właściwości jednego z najczęściej stosowanych i najlepiej poznanych przedstawicieli grupy – ramiprilu, podając 10 powodów przemawiających za jego wyborem.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Wełnicki , M. (2017). 10 powodów, dla których warto stosować ramipril . Medycyna Faktów , 10(3(36), 276-280. Pobrano z https://journalsmededu.pl/index.php/jebm/article/view/2139
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Meredith P.A., Elliott H.L.: FDA guidelines on trough:peak ratios in the evaluation of antihypertensive agents. J. Cardiovasc. Pharmacol. 1994; 23(supl. 5): S26-30.
2. Meredith P.A.: New FDA guidelines on the treatment of hypertension: comparison of different therapeutic classes according to trough/peak blood pressure responses. Arch. Mal. Coeur. Vaiss. 1994; 87(11): 1423-1429.
3. Chi V.X., Chau N.P.: Antihypertensive effect of drugs: statistical distribution of the trough-to-peak ratio. Biometrics 1996; 52(1): 286-290.
4. Rutz-Danielczak A., Tykarski A.: Ramipril. Biblioteka Czasopisma Nadciśnienie Tętnicze. Via Medica, Gdańsk 2009.
5. Tykarski A., Kostka-Jeziorny K., Kawecka-Jaszcz K.: Chronoterapia nadciśnienia tętniczego. Arterial Hypertens. 2006; 10(3): 235-250.
6. Erman A., Winkler J., Chen-Gal B. et al.: Inhibition of angiotensin converting enzyme by ramipril in serum and tissue of man. Hypertens. 1991; 9: 1057-1062.
7. Piepho R.W.: Overview of the angiotensin-converting-enzyme inhibitors. Am. J. Health Syst. Pharm. 2000; 57(supl. 1): S3-S7.
8. Tykarski A., Widecka K., Filipiak K.J.: Zasady postępowania w nadciśnieniu tętniczym – 2015 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Próba komentarza na temat zmian i ich zasadności. Nadciśn. Tętn. w Prakt. 2015; 2: 71-96.
9. Widecka K., Szymański F.M., Filipiak K.J. et al.: Stanowisko ekspertów dotyczące hiperurykemii i jej leczenia u pacjentów z wysokim ryzykiem sercowo-naczyniowym. Arterial Hypertens. 2017; 21(1): 1-9.
10. Kaplan N.M.: The CARE Study: a postmarketing evaluation of ramipril in 11,100 patients. The Clinical Altace Real-World Efficacy (CARE) Investigators. Clin. Ther. 1996; 18(4): 658-670.
11. Scheen A.J.: DREAM study: prevention of type 2 diabetes with ramipril and/or rosiglitazone in persons with dysglycaemia but no cardiovascular desease. Rev. Med. Liege. 2006; 61(10): 728-732.
12. Lièvre M., Guéret P., Gayet C. et al.: Remission of left ventricular hypertrophy with ramipril independently of blood pressure changes: the HYCAR study (cardiac hypertrophy and ramipril). Arch. Mal. Coeur Vaiss. 1995; 88(Spec. No. 2): 35-42.
13. MacMahon S., Sharpe N., Gamble G. et. al.: Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART-2 Collaborative Research Group. Prevention of Atherosclerosis with Ramipril. J. Am. Coll. Cardiol. 2000; 36(2): 438-443.
14. Agabiti-Rosei E., Ambrosioni E., Dal Palù C.: ACE inhibitor ramipril is more effective than the beta-blocker atenolol in reducing left ventricular mass in hypertension. Results of the RACE (ramipril cardioprotective evaluation) study on behalf of the RACE study group. J. Hypertens. 1995; 13(11): 1325-1334.
15. Hall A.S., Winter C., Bogle S.M. et al.: The Acute Infarction Ramipril Efficacy (AIRE) Study: rationale, design, organization, and outcome definitions. J. Cardiovasc. Pharmacol. 1991; 18(supl. 2): S105-S109.
16. Hall A.S., Murray G.D., Ball S.G. et al.: Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Lancet 1997; 349: 1493-1497.
17. Bosch J., Lonn E., Pogue J. et al.; on behalf of HOPE/HOPE-TOO Study Investigators: Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension. Circulation 2005; 112(9): 1339-1346.
18. Borghi C., Cosentino E.R., Rinaldi E.R. et al.: Effect of zofenopril and ramipril on cardiovascular mortality in patients with chronic heart failure. Am. J. Cardiol. 2013; 112(1): 90-93. DOI: 10.1016/j.amjcard.2013.02.058.
19. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000; 355(9200): 253-259.
20. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia): Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997; 349: 1857-1863.
21. Bull S., Loudon M., Francis J.M. et al.: A prospective, double-blind, randomized controlled trial of the angiotensin-converting enzyme inhibitor Ramipril In Aortic Stenosis (RIAS trial). Eur. Heart J. Cardiovasc. Imaging 2015; 16(8): 834-841.
22. Bang C.N., Greve A.M., Køber L. et al.: Renin-angiotensin system inhibition is not associated with increased sudden cardiac death, cardiovascular mortality or all-cause mortality in patients with aortic stenosis. Int. J. Cardiol. 2014; 175(3): 492-498.
23. Shahin Y., Cockcroft J.R., Chetter I.C.: Randomized clinical trial of angiotensin-converting enzyme inhibitor, ramipril, in patients with intermittent claudication. Br. J. Surg. 2013; 100(9): 1154-1163.
24. Hunter M.R., Cahoon W.D. Jr, Lowe D.K.: Angiotensin-converting enzyme inhibitors for intermittent claudication associated with peripheral arterial disease. Ann. Pharmacother. 2013; 47(11): 1552-1557.
2. Meredith P.A.: New FDA guidelines on the treatment of hypertension: comparison of different therapeutic classes according to trough/peak blood pressure responses. Arch. Mal. Coeur. Vaiss. 1994; 87(11): 1423-1429.
3. Chi V.X., Chau N.P.: Antihypertensive effect of drugs: statistical distribution of the trough-to-peak ratio. Biometrics 1996; 52(1): 286-290.
4. Rutz-Danielczak A., Tykarski A.: Ramipril. Biblioteka Czasopisma Nadciśnienie Tętnicze. Via Medica, Gdańsk 2009.
5. Tykarski A., Kostka-Jeziorny K., Kawecka-Jaszcz K.: Chronoterapia nadciśnienia tętniczego. Arterial Hypertens. 2006; 10(3): 235-250.
6. Erman A., Winkler J., Chen-Gal B. et al.: Inhibition of angiotensin converting enzyme by ramipril in serum and tissue of man. Hypertens. 1991; 9: 1057-1062.
7. Piepho R.W.: Overview of the angiotensin-converting-enzyme inhibitors. Am. J. Health Syst. Pharm. 2000; 57(supl. 1): S3-S7.
8. Tykarski A., Widecka K., Filipiak K.J.: Zasady postępowania w nadciśnieniu tętniczym – 2015 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Próba komentarza na temat zmian i ich zasadności. Nadciśn. Tętn. w Prakt. 2015; 2: 71-96.
9. Widecka K., Szymański F.M., Filipiak K.J. et al.: Stanowisko ekspertów dotyczące hiperurykemii i jej leczenia u pacjentów z wysokim ryzykiem sercowo-naczyniowym. Arterial Hypertens. 2017; 21(1): 1-9.
10. Kaplan N.M.: The CARE Study: a postmarketing evaluation of ramipril in 11,100 patients. The Clinical Altace Real-World Efficacy (CARE) Investigators. Clin. Ther. 1996; 18(4): 658-670.
11. Scheen A.J.: DREAM study: prevention of type 2 diabetes with ramipril and/or rosiglitazone in persons with dysglycaemia but no cardiovascular desease. Rev. Med. Liege. 2006; 61(10): 728-732.
12. Lièvre M., Guéret P., Gayet C. et al.: Remission of left ventricular hypertrophy with ramipril independently of blood pressure changes: the HYCAR study (cardiac hypertrophy and ramipril). Arch. Mal. Coeur Vaiss. 1995; 88(Spec. No. 2): 35-42.
13. MacMahon S., Sharpe N., Gamble G. et. al.: Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART-2 Collaborative Research Group. Prevention of Atherosclerosis with Ramipril. J. Am. Coll. Cardiol. 2000; 36(2): 438-443.
14. Agabiti-Rosei E., Ambrosioni E., Dal Palù C.: ACE inhibitor ramipril is more effective than the beta-blocker atenolol in reducing left ventricular mass in hypertension. Results of the RACE (ramipril cardioprotective evaluation) study on behalf of the RACE study group. J. Hypertens. 1995; 13(11): 1325-1334.
15. Hall A.S., Winter C., Bogle S.M. et al.: The Acute Infarction Ramipril Efficacy (AIRE) Study: rationale, design, organization, and outcome definitions. J. Cardiovasc. Pharmacol. 1991; 18(supl. 2): S105-S109.
16. Hall A.S., Murray G.D., Ball S.G. et al.: Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Lancet 1997; 349: 1493-1497.
17. Bosch J., Lonn E., Pogue J. et al.; on behalf of HOPE/HOPE-TOO Study Investigators: Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension. Circulation 2005; 112(9): 1339-1346.
18. Borghi C., Cosentino E.R., Rinaldi E.R. et al.: Effect of zofenopril and ramipril on cardiovascular mortality in patients with chronic heart failure. Am. J. Cardiol. 2013; 112(1): 90-93. DOI: 10.1016/j.amjcard.2013.02.058.
19. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000; 355(9200): 253-259.
20. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia): Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997; 349: 1857-1863.
21. Bull S., Loudon M., Francis J.M. et al.: A prospective, double-blind, randomized controlled trial of the angiotensin-converting enzyme inhibitor Ramipril In Aortic Stenosis (RIAS trial). Eur. Heart J. Cardiovasc. Imaging 2015; 16(8): 834-841.
22. Bang C.N., Greve A.M., Køber L. et al.: Renin-angiotensin system inhibition is not associated with increased sudden cardiac death, cardiovascular mortality or all-cause mortality in patients with aortic stenosis. Int. J. Cardiol. 2014; 175(3): 492-498.
23. Shahin Y., Cockcroft J.R., Chetter I.C.: Randomized clinical trial of angiotensin-converting enzyme inhibitor, ramipril, in patients with intermittent claudication. Br. J. Surg. 2013; 100(9): 1154-1163.
24. Hunter M.R., Cahoon W.D. Jr, Lowe D.K.: Angiotensin-converting enzyme inhibitors for intermittent claudication associated with peripheral arterial disease. Ann. Pharmacother. 2013; 47(11): 1552-1557.